(AOF) – Median Technologies announces that it has received the agreement of the European Investment Bank for the drawing of the last tranche of the loan granted on December 18, 2019 and renegotiated at the end of 2022. The specialist in innovative software solutions in health and health services The imagery specifies that the funds of 8.5 million euros corresponding to the last tranche will be released at the beginning of January 2024. Tranche B of the EIB financing “will allow us to continue our investment plan for eyonis and its programs early diagnosis of cancers”, announces boss Fredrik Brag.
“Combined with previous financing gathered in 2023, this operation strengthens our financial visibility and positions our cash flow horizon for the first half of 2025,” he specifies.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.